Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm Announces Second Quarter 2020 Financial Results
Second Quarter Revenue Decreased 8 Percent to $26.1 Million Filed for FDA Emergency Use Authorization for COVID-19 Saliva-based Test Multi-Site U.S. Study of COVID-19 Patients Utilizes Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay Fluidigm Selected for $37 Million Project under
View HTML
Toggle Summary Fluidigm and De Novo Software to Offer Mass Cytometry Customers a Streamlined Solution for Data Analysis
License for De Novo Software’s FCS Express 7 Flow to be Provided to Customers Purchasing Fluidigm Helios and Hyperion Imaging Systems SOUTH SAN FRANCISCO, Calif. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to
View HTML
Toggle Summary Fluidigm Selected for $37 Million Project under National Institutes of Health RADx Initiative
Fluidigm among First Seven Companies to Advance in Historic and Rapidly Instituted Program to Support Development and Commercialization of Innovative COVID-19 Testing Technologies SOUTH SAN FRANCISCO, Calif. , July 31, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative
View HTML
Toggle Summary GnomeDX Files for FDA Emergency Use Authorization for Rapid Turnaround Real-Time RT-PCR COVID-19 Test Utilizing the Fluidigm Biomark HD Platform
Test Intended to Expand Availability of COVID-19 Screening Resources in Central Ohio Workflow with Real-Time PCR Using Fluidigm Microfluidics Technology and Reagents Increasing Number of Labs Adopting the Fluidigm   High-Throughput Testing Model SOUTH SAN FRANCISCO, Calif., and COLUMBUS, Ohio ,
View HTML
Toggle Summary Fluidigm Announces Conference Call and Webcast of Second Quarter 2020 Financial Results
SOUTH SAN FRANCISCO, Calif. , July 06, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report second quarter 2020 financial results on Thursday,
View HTML
Toggle Summary Multi-Site Study of COVID-19 Patients Utilizing Fluidigm Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay
Tracking the Immune Response of Patients Hospitalized with COVID-19 in 10 Research Sites Across the United States Study May Inform Recommendations for COVID-19 Care, New Strategies for Treatments SOUTH SAN FRANCISCO, Calif. , June 29, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an
View HTML
Toggle Summary Integrated Genetics Lab Services Conducting COVID-19 Testing in Spain Utilizing Fluidigm Biomark HD Platform
iGLS Among Labs Chosen by Spanish Health Authorities to Expand SARS-CoV-2 Screening End-to-End Workflow from Extraction through Real-Time PCR Using Fluidigm Microfluidics Technology and Reagents Screening of Critical Populations Under Way , Capacity of Up to 6,000 Tests Per Day on Single Instrument
View HTML
Toggle Summary New Collaboration with Bethyl Laboratories Expands Antibody Offerings for Hyperion Imaging System
Fluidigm to Be Exclusive Distributor for Bethyl Antibodies for Use with Imaging Mass Cytometry Providing Researchers with Expanded Capabilities in Interrogating the Tissue Microenvironment SOUTH SAN FRANCISCO, Calif. , June 17, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an
View HTML
Toggle Summary Fluidigm Files for FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Test for COVID-19
Extraction-Free, Real-Time PCR Workflow with Capacity of Up to 6,000 Tests per Day Easy-to-Administer Saliva Test Would Eliminate Need for Invasive Nasopharyngeal Swab High-Throughput Assay Developed in Collaboration with Washington University School of Medicine SOUTH SAN FRANCISCO, Calif.
View HTML
Toggle Summary University of Paris Researchers Utilize Fluidigm Mass Cytometry and Maxpar Direct Immune Profiling Assay to Identify Distinct Phenotype among Patients with Severe COVID-19
Study Suggests That Type I IFN Deficiency in the Blood Could Help Define a High-Risk Population SOUTH SAN FRANCISCO, Calif. , May 19, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health
View HTML